Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 55

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 55
---
 us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce
or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that
we would otherwise prefer to develop and market ourselves.

We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.

As a public company, we incur significant legal,
accounting and other expenses under the Sarbanes-Oxley Act of 2002, (the “Sarbanes-Oxley Act”), as well as rules subsequently
implemented by the SEC, and the rules of The Nasdaq Stock Market LLC (“Nasdaq”). These rules impose various requirements
on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate
corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time
to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make
some activities more time-consuming and costly. For example, these rules and regulations make it more difficult and more expensive
for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur
substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain
qualified persons to serve on our Board, our Board committees or as executive officers.

The Sarbanes-Oxley Act requires, among other things,
that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required
to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness
of those controls, as required by Section 404 of the Sarbanes-Oxley Act. These efforts to comply with Section 404 and related
regulations have required, and continue to require, the commitment of significant financial and managerial resources. While we anticipate
maintaining the integrity of our internal controls over financial reporting and all other aspects of Section 404, we cannot be certain
that a material weakness will not be identified when we test the effectiveness of our control systems in the future. If a material weakness
is identified, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional
financial and management